Document is current
Any future updates will be listed below
-
Authors
Hunaut, Thomas
Gérard, Laura
Hercent, Agathe
Hentic, Olivia
Buecher, Bruno
Lepage, Come
Lecomte, Thierry
Thuillier, Philippe
Do Cao, Christine
Durand, Alice
Roquin, Guillaume
Lepere, Céline
Lebras, Maelle
Dominguez, Sophie
Baltzinger, Philippe
Devulder, Pierre
Guedj, Nathalie
Brixi, Hedia
Féron, Thomas
Cros, Jérôme
Pasmant, Eric
Lombard-Bohas, Catherine
Walter, Thomas
Cadiot, Guillaume
de Mestier, Louis
-
Funding
Funding for this research was provided by:
Société Nationale Française de Gastro-Entérologie
Groupe d'étude des tumeurs endocrines
- License Information
-
More Information
Article History
Received: 17 November 2025
Accepted: 9 March 2026
First Online: 19 March 2026
Declarations
:
: This study was performed according to the ethical guidelines of the Declaration of Helsinki and was approved by Institutional Review Board: Comité de Protection des Personnes Sud-Méditerranée II reference: 217-R35.
: Informed consent was obtained from all individual participants included in the study.
: - Laura Gérard: Consulting fees from Novartis and Ipsen- Come Lepage: consulting fees from Novartis and Ipsen - Thierry Lecomte: consulting fees from Ipsen and Novartis- Christine DoCao: non-financial support from Novartis, Ipsen and Correvio- Celine Lepere: conference invitation from Correvio and Ipsen- Hedia Brixi: consulting fees from Novartis- Jérôme Cros: consulting fees from Novartis and Boehringer Ingelheim- Thomas Walter: Gilead, consulting fees from Ipsen, Oranomed, ITM, Novartis. Conference invitation from Ispen, Pierre Fabre, Novartis. - Guillaume Cadiot: consulting fees from Novartis- Louis de Mestier: consulting fees from Novartis, Boehringer Ingelheim, Esteve, Ipsen. Research fees from Boehringer Ingelheim, Esteve. No conflicts of interest are claimed by the remaining authors.
: This study was registered atClinicalTrials.gov, ID NCT03622333, date 28/05/2018.
